Elevance Health is executing a disciplined capital allocation strategy that balances shareholder returns with long-term business expansion. In the first quarter of 2026, the company generated $4.3 billion in operating cash flow, up sharply from $1 billion a year ago, and expects full-year operating cash flow of at least $5.5 billion. It returned around $1.5 billion to shareholders through $376 million in dividends and $1.1 billion in share repurchases, with $5.6 billion remaining under its share repurchase authorization as of March 31, 2026. The company is also investing in Carelon's capabilities across pharmacy, behavioral health, home-based care, and value-based care, while scaling AI to improve efficiency. Elevance Health's return on invested capital of 8.3% exceeds the industry average of 6.6%, and its shares have risen 19.9% year-to-date, outperforming the industry's 0.1% decline.
Humana Inc
UnitedHealth Group IncorporatedElevance Health IncElevance Health reported strong operating cash flow, share buybacks, dividends, and a high return on invested capital, all positive for shareholders.